QLS4131

DRUG2 trials

Sponsors

Qilu Pharmaceutical Co., Ltd., Institute of Hematology & Blood Diseases Hospital, China

Conditions

AL AmyloidosisMalignant Plasma Cell Neoplasms

Phase 2

QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

Not yet recruitingNCT07560449

Qilu Pharmaceutical Co., Ltd.Malignant Plasma Cell Neoplasms

Start: 2026-06-01End: 2030-06-01Target: 162Updated: 2026-05-01

BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)

Not yet recruitingNCT07751471

Institute of Hematology & Blood Diseases Hospital, ChinaAL Amyloidosis

Start: 2026-07-20End: 2028-12-31Target: 20Updated: 2026-08-07